GMMMG logo

NHS photos

NHS logo

GMMMG Consultations

 

On this page you will find proposed changes that are currently going through the GMMMG approval process. This will include consultations on proposed RAG status, updated Formulary Chapters, Pathways or other GMMMG Guidance. You will be able to comment on current proposals via the links in the table below.

Title

Information

Feedback

End date

27

GM asthma management plan 2018

The GM asthma working group have updated the GM asthma management plan following publication of NICE’s asthma guideline NG80.

The main updates to the GM asthma management plan are as follows:

  • Updated to reflect the addition of leukotriene receptor antagonist (montelukast – the only one now) with guidance on deciding between LTRA or LABA/ICS
  • The GM plan differs from NICE in that the use of a SABA alone is not included but reflects BTS in that the first step is use of a low dose ICS. It was felt that going back to a SABA-alone option was a retrograde step (ref NRAD report: Overuse of short-acting bronchodilators is a key indicator of poor asthma control and of higher risk of exacerbation and death.)
  • As previously, the GM plan includes a smaller number of devices where we have aimed for device consistency throughout which should improve familiarity and ease of use of products for patients and prescribers.
  • DuoResp has been replaced by Easyhaler throughout (more economical, provides device consistency)

Please submit any comments using the feedback form. This consultation will close at 5pm on Friday 29th June 2018.

Industry are invited to comment on factual inaccuracy only.

Feedback Form

5pm Friday
29th June 2018

26

GM resource pack for opioid prescribing for chronic pain

Under the direction of the GM Clinical Standards Board, the Pathways and Guidelines Development Subgroup are working to develop a GM resource pack for opioid prescribing for chronic pain. Wigan Borough CCG have produced a resource pack which we are looking to implement across GM. This document is now open for GM-wide consultation in line with the GMMMG approval process. Please submit any comments using the feedback form. This consultation will close at 5pm on Friday 15th June 2018.

Industry are invited to comment on factual inaccuracy only.

Feedback form

5pm Friday
15th June 2018

25

PCSK9 inhibitor Blueteq forms
(this link is to a zipped file containing 4 PDF documents)

We are asking for comments on the PCSK9 inhibitor Blueteq forms which are currently live on the system.

The questions appear to be in line with NICE and GMMMG recommendation but are wordy. However the clinician response are mainly tick boxes so should be quick to complete.

Please feedback any changes you think may be beneficial to the Greater Manchester services using these PCSK9 inhibitor forms.

A summary of the questions on the initiation form are below

Q1 is asking for standard treatment prior to biosimilar (tick for why discontinued and tick which drugs tried)

Q2 is asking for LDLc scores; it could be removed but the LDL-c may be used by trusts to monitor the change in LDLc from initiation to continuation

Q3 is a tick for which category the patient fits into (matching table 1 in NICE)Q4 could go if we assume the patient is told they may have their treatment stopped

Q5 is info regarding when a continuation is expected.

Feedback Form

5pm Friday
1st June 2018

24

FMESG - proposed actions for consultation
[Link removed - consultation closed]

The following actions were proposed at the March 2018 FMESG meeting, approved in principle by GMMMG in April, and are now open for GM wide consultation. Comments are invited up until 5pm Tuesday 15th May 2018
[Links removed - consultation closed]

Feedback Form
[Link removed - consultation closed]

5pm Tuesday
15th May 2018

23

GM Model Framework for dermatology services

Under direction of the GM Directors of Commissioning  the GM Dermatology Group are developing the GM Model Framework for dermatology services. The group has produced a series of educational tools which will help to improve confidence of managing skin in primary care and upskill clinicians in primary care at the same time.

Included in the educational pack is:

5pm Wednesday
30th May 2018

A GM pathway of care from primary care to tertiary care

Acne management

Eczema management

Psoriasis management

Warts management

Actinic Keratosis management

Refreshed skin chapter

2WW pathway

Emollient ladder

Steroid ladder

 

Feedback Form 23a

Feedback Form 23b

Feedback Form 23c

Feedback Form 23d

Feedback Form 23e

 

Feedback Form 23f

Feedback Form 23g

Feedback Form 23h

 

A number of these are now opened (see links above) for GM wide consultation in line with the GMMMG approval process. Please submit any comments using the appropriate feedback form links above, this consultation will close at 5pm Wednesday 30th May 2018.

Industry are invited to comment on factual inaccuracy only.

22

Revised DNP and grey lists for consultation

The Greater Manchester DNP and grey lists have been revised to reflect recent NHS England guidance. Please note that the list contains items previously considered by GMMMG and not included in the NHS England list. Changes to these items are purely editorial, in order to harmonise wording throughout. The list also contains three new items to be considered for inclusion.

The revised list is now open for GM-wide consultation for 6 weeks. Industry are invited to comment on factual inaccuracies only. Following consultation the list will be taken forward to AGG for policy development. Comments are invited up until 5pm on Tuesday 22nd May 2018 and should be submitted here.

Feedback Form

5pm Tuesday
22nd May 2018

21

Ciclosporin for childhood nephrotic syndrome
[Link removed - consultation closed]

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for  ciclosporin for childhood nephrotic syndrome [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018.

Feedback Form
[Link removed - consultation closed]

5pm Friday
18th May 2018

20

Sulfasalazine for inflammatory bowel disease
[Link removed - consultation closed]

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for  sulfasalazine for inflammatory bowel disease [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018.

Feedback Form
[Link removed - consultation closed]

5pm Friday
18th May 2018

19

Domperidone for paediatric gastro-oesophageal reflux disease
[Link removed - consultation closed]

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for domperidone for paediatric gastro-oesophageal reflux disease [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018.

Feedback Form
[Link removed - consultation closed]

5pm Friday
18th May 2018

18

Disulfiram for alcohol dependence
[Link removed - consultation closed]

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for disulfiram for alcohol dependence [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018.

Feedback Form
[Link removed - consultation closed]

5pm Friday
18th May 2018

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer